247 related articles for article (PubMed ID: 20569296)
21. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.
Savoia P; Ortoncelli M; Quaglino P; Bernengo MG
Dermatol Surg; 2006 Aug; 32(8):1097-102. PubMed ID: 16918576
[No Abstract] [Full Text] [Related]
23. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
Price VE; Fletcher JA; Zielenska M; Cole W; Viero S; Manson DE; Stuart M; Pappo AS
Pediatr Blood Cancer; 2005 May; 44(5):511-5. PubMed ID: 15503291
[TBL] [Abstract][Full Text] [Related]
25. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
McArthur G
Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
[TBL] [Abstract][Full Text] [Related]
27. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
28. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
30. Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans.
Ortiz AE; Wu JJ; Linden KG
Dermatol Surg; 2008 Aug; 34(8):1151. PubMed ID: 18513297
[No Abstract] [Full Text] [Related]
31. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans.
Mizutani K; Tamada Y; Hara K; Tsuzuki T; Saeki H; Tamaki K; Matsumoto Y
Br J Dermatol; 2004 Jul; 151(1):235-7. PubMed ID: 15270901
[No Abstract] [Full Text] [Related]
33. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
Fattoruso SI; Visca P; Lopez M
Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
[TBL] [Abstract][Full Text] [Related]
34. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
Mentzel T; Schärer L; Kazakov DV; Michal M
Am J Dermatopathol; 2007 Oct; 29(5):443-8. PubMed ID: 17890911
[TBL] [Abstract][Full Text] [Related]
35. Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient.
Fava P; Stroppiana E; Savoia P; Bernengo MG
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):244-5. PubMed ID: 19694892
[No Abstract] [Full Text] [Related]
36. Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery.
Jeon IK; Kim JH; Kim SE; Kim SC; Roh MR
J Dermatol; 2013 Apr; 40(4):288-9. PubMed ID: 23293988
[No Abstract] [Full Text] [Related]
37. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
[TBL] [Abstract][Full Text] [Related]
38. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
39. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
40. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
Kallini JR; Khachemoune A
J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
